Forbes.com
LAKE FOREST, Ill. - Eye care products maker Akorn Inc. said Wednesday that federal regulators approved its topical eye anesthetic Akten.
Akorn said the Food and Drug Administration approved its Ophthalmic Gel 3.5 percent. It will launch the drug later this month for use in procedures including cataract surgery, refractive surgery and Lasik surgery. The company said Akten is the first new ocular anesthetic to get FDA approval in 40 years.